# A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

> **NCT02588651** · PHASE2 · COMPLETED · sponsor: **Deepa Jagadeesh** · enrollment: 23 (actual)

## Conditions studied

- T-cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Hepato-splenic T-cell Lymphoma
- Adult T-cell Leukemia/Lymphoma
- Enteropathy Associated T-cell Lymphoma
- NK T-cell Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin

## Key facts

- **NCT ID:** NCT02588651
- **Lead sponsor:** Deepa Jagadeesh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-17
- **Primary completion:** 2024-10-14
- **Final completion:** 2024-10-14
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588651, "A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02588651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*